JP2011520977A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520977A5
JP2011520977A5 JP2011510691A JP2011510691A JP2011520977A5 JP 2011520977 A5 JP2011520977 A5 JP 2011520977A5 JP 2011510691 A JP2011510691 A JP 2011510691A JP 2011510691 A JP2011510691 A JP 2011510691A JP 2011520977 A5 JP2011520977 A5 JP 2011520977A5
Authority
JP
Japan
Prior art keywords
composition
pharmaceutically acceptable
solvate
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011510691A
Other languages
English (en)
Japanese (ja)
Other versions
JP5757864B2 (ja
JP2011520977A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/044743 external-priority patent/WO2009143295A1/en
Publication of JP2011520977A publication Critical patent/JP2011520977A/ja
Publication of JP2011520977A5 publication Critical patent/JP2011520977A5/ja
Application granted granted Critical
Publication of JP5757864B2 publication Critical patent/JP5757864B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011510691A 2008-05-20 2009-05-20 水溶性アセトアミノフェン類似体 Expired - Fee Related JP5757864B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5477408P 2008-05-20 2008-05-20
US61/054,774 2008-05-20
PCT/US2009/044743 WO2009143295A1 (en) 2008-05-20 2009-05-20 Water-soluble acetaminophen analogs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014049672A Division JP2014111658A (ja) 2008-05-20 2014-03-13 水溶性アセトアミノフェン類似体

Publications (3)

Publication Number Publication Date
JP2011520977A JP2011520977A (ja) 2011-07-21
JP2011520977A5 true JP2011520977A5 (US07981874-20110719-C00313.png) 2012-07-05
JP5757864B2 JP5757864B2 (ja) 2015-08-05

Family

ID=41340538

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2011510691A Expired - Fee Related JP5757864B2 (ja) 2008-05-20 2009-05-20 水溶性アセトアミノフェン類似体
JP2014049672A Withdrawn JP2014111658A (ja) 2008-05-20 2014-03-13 水溶性アセトアミノフェン類似体
JP2016016971A Expired - Fee Related JP6063072B2 (ja) 2008-05-20 2016-02-01 水溶性アセトアミノフェン類似体
JP2016242968A Withdrawn JP2017057217A (ja) 2008-05-20 2016-12-15 水溶性アセトアミノフェン類似体
JP2018098716A Withdrawn JP2018135392A (ja) 2008-05-20 2018-05-23 水溶性アセトアミノフェン類似体
JP2020074690A Withdrawn JP2020114876A (ja) 2008-05-20 2020-04-20 水溶性アセトアミノフェン類似体

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2014049672A Withdrawn JP2014111658A (ja) 2008-05-20 2014-03-13 水溶性アセトアミノフェン類似体
JP2016016971A Expired - Fee Related JP6063072B2 (ja) 2008-05-20 2016-02-01 水溶性アセトアミノフェン類似体
JP2016242968A Withdrawn JP2017057217A (ja) 2008-05-20 2016-12-15 水溶性アセトアミノフェン類似体
JP2018098716A Withdrawn JP2018135392A (ja) 2008-05-20 2018-05-23 水溶性アセトアミノフェン類似体
JP2020074690A Withdrawn JP2020114876A (ja) 2008-05-20 2020-04-20 水溶性アセトアミノフェン類似体

Country Status (12)

Country Link
US (4) US20110212926A1 (US07981874-20110719-C00313.png)
EP (1) EP2291348A4 (US07981874-20110719-C00313.png)
JP (6) JP5757864B2 (US07981874-20110719-C00313.png)
KR (1) KR101698028B1 (US07981874-20110719-C00313.png)
CN (2) CN102149672A (US07981874-20110719-C00313.png)
AU (1) AU2009249067A1 (US07981874-20110719-C00313.png)
BR (1) BRPI0912326A2 (US07981874-20110719-C00313.png)
CA (1) CA2724877C (US07981874-20110719-C00313.png)
IL (1) IL209382A0 (US07981874-20110719-C00313.png)
MX (1) MX2010012648A (US07981874-20110719-C00313.png)
RU (1) RU2010151952A (US07981874-20110719-C00313.png)
WO (1) WO2009143295A1 (US07981874-20110719-C00313.png)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143295A1 (en) 2008-05-20 2009-11-26 Neurogesx, Inc. Water-soluble acetaminophen analogs
RU2010151951A (ru) 2008-05-20 2012-06-27 Ньюроджесэкс, Инк. (Us) Общие пролекарства гепатопротектора и ацетаминофена
EP2291084A4 (en) 2008-05-20 2012-04-25 Neurogesx Inc CARBONATE PRODRUGS AND METHOD FOR THEIR USE
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
US9359376B2 (en) * 2011-04-08 2016-06-07 Sphaera Pharma Pte. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
WO2013044064A1 (en) 2011-09-22 2013-03-28 Neurogesx, Inc. Acetaminophen conjugates, compositions and methods of use thereof
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US11311512B2 (en) 2014-08-12 2022-04-26 Monash University Lymph directing prodrugs
CA2964628A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
PL3209302T3 (pl) 2014-10-21 2019-10-31 Abbvie Inc Proleki karbidopy i L-dopy oraz ich zastosowanie do leczenia choroby Parkinsona
EP3265097A4 (en) * 2015-03-03 2018-11-07 Kindred Biosciences Inc. Compositions and methods for treatment and prevention of pyrexia in horses
CN108137482B (zh) 2015-09-08 2024-03-15 莫纳什大学 定向淋巴的前药
EP3445346A1 (en) * 2016-04-20 2019-02-27 AbbVie Inc. Carbidopa and l-dopa prodrugs and methods of use
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
CA3077739A1 (en) 2017-08-29 2019-03-07 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
WO2019126378A1 (en) 2017-12-19 2019-06-27 Ariya Therapeutics, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11389409B2 (en) * 2019-08-30 2022-07-19 Remedy Diagnostics LLC Transdermal device comprising acetaminophen prodrug
WO2021159021A1 (en) 2020-02-05 2021-08-12 Puretech Lyt, Inc. Lipid prodrugs of neurosteroids

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2444043A1 (fr) * 1978-12-15 1980-07-11 Bottu Nouveau derive du paracetamol, son procede de preparation et son utilisation en therapeutique
DK406686D0 (da) * 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US5001115A (en) * 1989-05-17 1991-03-19 University Of Florida Prodrugs of biologically active hydroxyaromatic compounds
JPH06501448A (ja) * 1989-12-26 1994-02-17 ノバ ファーマシューティカル コーポレイション 無水物プロドラッグ組成物
US5627165A (en) * 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US5272171A (en) * 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
US6750216B2 (en) * 1996-03-08 2004-06-15 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
IT1282736B1 (it) * 1996-05-21 1998-03-31 Angelini Ricerche Spa Uso di derivati del p-amminofenolo per preparare composizioni farmaceutiche utili nel trattamento di malattie neurodegenerative
EP0981532B1 (en) * 1997-05-15 2002-08-28 Drug Innovation & Design, Inc. Acyclovir diester derivatives
CA2317008C (en) * 1997-12-31 2009-01-20 The University Of Kansas Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
DE69912250T2 (de) * 1998-01-29 2004-07-29 Bristol-Myers Squibb Co., Wallingford Phosphorylierte derivate des diaryl 1,3,4 oxadiazolon
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US8231899B2 (en) * 1998-09-10 2012-07-31 Nycomed Danmark Aps Quick release pharmaceutical compositions of drug substances
EP1109534B1 (en) * 1998-09-10 2003-02-12 Nycomed Danmark A/S Quick release pharmaceutical compositions of drug substances
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6362172B2 (en) 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
CZ20023116A3 (cs) * 2000-03-29 2003-01-15 Altana Pharma Ag Alkylované imidazopyridinové sloučeniny
BR0210179A (pt) * 2001-06-05 2004-04-27 Control Delivery Sys Inc Compostos analgésicos de liberação sustentada
US6825204B2 (en) * 2002-02-05 2004-11-30 Bristol-Myers Squibb Company N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals containing thereof
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
WO2004043493A1 (en) * 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
WO2004078180A2 (en) * 2003-03-03 2004-09-16 Guilford Pharmaceuticals Inc. Naaladase inhibitors for treating opioid tolerance
WO2004082620A2 (en) * 2003-03-13 2004-09-30 Controlled Chemicals, Inc. Oxycodone conjugates with lower the abuse potential and extended duration of action
AU2003901813A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Pharmaceutical derivatives
US20050080260A1 (en) * 2003-04-22 2005-04-14 Mills Randell L. Preparation of prodrugs for selective drug delivery
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20070093457A1 (en) * 2004-02-11 2007-04-26 Nadir Arber Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid
US7718633B2 (en) 2004-07-06 2010-05-18 Abbott Laboratories Prodrugs of HIV protease inhibitors
MX2009006007A (es) 2006-12-05 2009-07-17 Neurogesx Inc Profarmacos y metodos para hacer y usar los mismos.
WO2009143295A1 (en) 2008-05-20 2009-11-26 Neurogesx, Inc. Water-soluble acetaminophen analogs
EP2291084A4 (en) * 2008-05-20 2012-04-25 Neurogesx Inc CARBONATE PRODRUGS AND METHOD FOR THEIR USE
RU2010151951A (ru) 2008-05-20 2012-06-27 Ньюроджесэкс, Инк. (Us) Общие пролекарства гепатопротектора и ацетаминофена
WO2010030781A2 (en) 2008-09-10 2010-03-18 Numed International, Inc. Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancer
EP2408443A1 (en) 2009-03-16 2012-01-25 Genmedica Therapeutics SL Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
WO2013044064A1 (en) 2011-09-22 2013-03-28 Neurogesx, Inc. Acetaminophen conjugates, compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2011520977A5 (US07981874-20110719-C00313.png)
RU2010151952A (ru) Водорастворимые аналоги ацетаминофена
JP2011523645A5 (US07981874-20110719-C00313.png)
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
RU2009118960A (ru) Комбинации ацетаминофена/ибуппрофена
TW200838545A (en) Therapeutic agent for painful disease
RU2013121788A (ru) Ингибиторы репликации вич
JP2013535437A5 (US07981874-20110719-C00313.png)
JP2014526503A5 (US07981874-20110719-C00313.png)
RU2010151951A (ru) Общие пролекарства гепатопротектора и ацетаминофена
JP5952890B2 (ja) 膵臓癌を治療するための医薬製剤
JP2019511529A5 (US07981874-20110719-C00313.png)
RU2006143659A (ru) Применение ребоксетина для лечения боли
ES2649492T3 (es) (S)-pirlindol o sus sales farmacéuticamente aceptables para uso en medicina
JP2013541583A5 (US07981874-20110719-C00313.png)
AR078170A1 (es) Metodos para el tratamiento de tumores cerebrales
JP2011518168A5 (US07981874-20110719-C00313.png)
CN102341393A (zh) 制备(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-甲氨基-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法
RU2005133665A (ru) Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
EP3491007A1 (en) Radiolabeled ligands for targeted pet/spect imaging and methods of their use
JP2014530204A5 (US07981874-20110719-C00313.png)
RU2015117483A (ru) Комбинации
ES2649491T3 (es) (R)-pirlindol y sus sales farmacéuticamente aceptables para uso en medicina
JP2009504668A5 (US07981874-20110719-C00313.png)
JP2014534229A5 (US07981874-20110719-C00313.png)